Neuren Pharmaceuticals Limited (AU:NEU) has released an update.
Neuren Pharmaceuticals has announced robust financial progress in Q3 2024, with DAYBUE™ achieving net sales surpassing US$250 million, triggering a US$50 million sales milestone payment. Additionally, Neuren will benefit from a one-third share of the US$150 million sale of a Priority Review Voucher by Acadia Pharmaceuticals. The company’s expected full-year income ranges between A$216 million and A$218 million, bolstered by royalties, milestone payments, and interest income.
For further insights into AU:NEU stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Disney (NYSE:DIS) Event in Brazil Captures Investor Attention
- The Likely Impact of Ford’s (NYSE:F) Plan to Pay for Chargers
- The Impact of Trump on Intel (NASDAQ:INTC)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
